The effects of inflammation and inflammatory mediators on nociceptive behaviour induced by ATP analogues in the rat.
1. We have studied the behavioural effects of intraplantar injections of adenosine 5'-triphosphate (ATP) and related compounds in freely moving rats and investigated whether these nociceptive effects are augmented in the presence of inflammatory mediators. 2. We find that in normal animals ATP and analogues produce dose-dependent nocifensive behaviour (seen as bursts of elevation of the treated hindpaw), and localized thermal hyperalgesia. The rank order of potency was: alpha,beta-methyleneadenosine 5'-triphosphate (alpha,beta-methylene ATP) > 2-methylthioadenosine triphosphate (2-methylthio ATP) > ATP. After neonatal treatment with capsaicin, to destroy small calibre primary sensory neurones, nocifensive behaviour was largely absent. 3. The effects of ATP analogues were assessed in three models of peripheral sensitization: 2 h after dilute intraplantar carrageenan (0.25% w v(-1)); 24 h after irradiation of the hindpaw with ultraviolet (U.V.) B; immediately following prostaglandin E2 (PGE2) treatment. In all models the effect of alpha,beta-methylene ATP was greatly augmented. After carrageenan, significant hindpaw-lifting behaviour activity was induced by injection of only 0.05 nmol of alpha,beta-methylene ATP, some 100 times less than necessary in normal skin. 4. Our data suggest that it is much more likely that endogenous levels of ATP will reach levels capable of exciting nociceptors in inflamed versus normal skin. Our data also suggest the involvement of P2X3 receptor subunits in ATP-induced nociception.
Neuroscience Research Centre, Guy's, King's College, London, England, UK.
S G
SG
Hamilton
A
A
Wade
S B
SB
McMahon
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D002211:Capsaicin / Q000494:pharmacology; D002351:Carrageenan / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005079:Excipients / Q000494:pharmacology; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology; D006930:Hyperalgesia / Q000139:chemically induced; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology*; D018836:Inflammation Mediators / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009619:Nociceptors / Q000187:drug effects* / Q000528:radiation effects; D010120:Oxytocics / Q000494:pharmacology; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control; D017288:Pain Threshold / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013873:Thionucleotides / Q000494:pharmacology; D014466:Ultraviolet Rays
D005079:Excipients; D018836:Inflammation Mediators; D010120:Oxytocics; D013873:Thionucleotides; D000255:Adenosine Triphosphate; D002351:Carrageenan; D015232:Dinoprostone; C002630:alpha,beta-methyleneadenosine 5'-triphosphate; D002211:Capsaicin; C008501:2-methylthio-ATP